Pfizer (PFE)
30.11
-0.31 (-1.02%)
NYSE · Last Trade: Oct 23rd, 10:02 AM EDT
News & Press Releases
3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomachmarketbeat.com
Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.
Via MarketBeat · October 23, 2026
Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb?fool.com
One of these pharma stocks offers more income, but the other offers a safer dividend.
Via The Motley Fool · October 23, 2026
Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy?fool.com
Here's how pharmaceutical stocks compare to biotech in terms of risk, rewards, and costs.
Via The Motley Fool · October 23, 2026
Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Optionmarketbeat.com
Prelude Therapeutics (NASDAQ:PRLD) outlined progress across three priority programs at a Chardan Capital investor session, emphasizing its recently initiated JAK2 program, an IND-cleared KAT6A degrader for breast cancer and a mutant calreticulin, or mCALR, program for myeloproliferative neoplasms.
Via MarketBeat · October 22, 2026
What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizerfool.com
They definitely matter... up to a point.
Via The Motley Fool · October 22, 2026
Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenuefool.com
Pfizer's revenue swung sharply lower before stabilizing, while Bristol Myers Squibb kept climbing steadily—a divergence that matters for long-term investors.
Via The Motley Fool · October 22, 2026
Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highsmarketbeat.com
Biotech and pharma stocks, tracked by the iShares Biotechnology ETF, have shown relative strength amid the tech sell-off, with Eli Lilly and Pfizer standing out as top performers.
Via MarketBeat · October 21, 2026
Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Noticefool.com
This company made headlines with its coronavirus vaccine.
Via The Motley Fool · October 21, 2026
A Look Back at Generic Pharmaceuticals Stocks’ Q2 Earnings: Viatris (NASDAQ:VTRS) Vs The Rest Of The Pack
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how generic pharmaceutical...
Via StockStory · October 20, 2026
Most Active S&P 500 Stocks in Today's Sessionchartmill.com
Via Chartmill · October 20, 2026
Pfizer's Stock Is Finally Showing Signs of Life. Could This Be the Start of a Much Bigger Rally?fool.com
The stock has outperformed the market this year, and it still looks heavily undervalued.
Via The Motley Fool · October 19, 2026
Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?fool.com
It has been a volatile year for the biotech.
Via The Motley Fool · October 18, 2026
Warren Buffett's Market Warning Is Hard to Ignore. But I'd Buy These 3 Stocks Anyway.fool.com
Not every company is at risk.
Via The Motley Fool · October 18, 2026
Here's What $10,000 in Each of These 5 High-Yield Dividend Stocks Could Pay You in a Yearfool.com
These five high-yield dividend stocks are paying yields of 5.88% to 16.72% -- but beware of a few key risks.
Via The Motley Fool · October 18, 2026
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?fool.com
The gene-editing biotech stock is down more than 12% this year.
Via The Motley Fool · October 17, 2026
Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipelinefool.com
BioNTech has billions in cash, and its oncology programs are moving into late-stage clinical trials.
Via The Motley Fool · October 17, 2026
Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividendsfool.com
You'd need to invest over $200,000 in the pharma leader at its current price.
Via The Motley Fool · October 16, 2026
Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe?fool.com
Pfizer's dividend yield is attractive, but investors need to know if it can maintain it.
Via The Motley Fool · October 16, 2026
Most-Active S&P 500 Stocks in Oct. 16, 2026 US Sessionchartmill.com
Via Chartmill · October 16, 2026
6 Blue Chip Stocks Trading Well Below Their Highsfool.com
Some look like bargains, but others could be value traps.
Via The Motley Fool · October 16, 2026
2 High-Yield Dividend Stocks Worth Buying Before 2026 Endsfool.com
Verizon and Pfizer pay generous dividends, and each has a different path to growth. Here's how income investors can lock in yield before year-end.
Via The Motley Fool · October 15, 2026
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?fool.com
AbbVie is raising its outlook with Skyrizi and Rinvoq offsetting Humira losses. Pfizer is rebuilding its pipeline around obesity drugs and key readouts expected over the next year.
Via The Motley Fool · October 15, 2026
Most active S&P500 stocks in Wednesday's sessionchartmill.com
Via Chartmill · October 14, 2026
Exploring the top movers within the S&P500 index during today's session.chartmill.com
Via Chartmill · October 14, 2026
Forget Treasury Bonds: This 6%-Yielding Pharma Stock Pays You to Wait for Its Pipelinefool.com
A reliable payout, a growing cancer treatment lineup, and improving guidance make this drugmaker worth a second look right now.
Via The Motley Fool · October 14, 2026